Same classification was concluded for cases U1 and U28 based on mutations in CREBBP, CARD11, EZH2, TNFRSF14, and TET2. Three cases (U5, U12, and U11) bore mutations that suggested contradicting classifications according to our current knowledge (CXCR4 or MYD88 indicative of LPL co-ocuring with TNFAIP3, KMT2D, CREBBP, KLF2, and TP53 all indicative of MZL), and were therefore not conclusive. Here, CREBBP is linked to marginal zone lymphoma.